You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

8 Results
Guidelines and Advice
Status: Current
ID: 24-3
Version: 2
Dec 2016
Guidelines and Advice
Status: In-Review
ID: 7-21
May 2016
Guidelines and Advice
Status: Archived
ID: 6-18
Version: 2
Jun 2016
Guidelines and Advice
Status: Current
ID: 3-14
Version: 2
Sep 2016
Guidelines and Advice
Status: Current
ID: GL-C50-25
Feb 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
buserelin,
bicalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • bicalutamide
ODB - General Benefit
  • goserelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bicalutamide,
goserelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
buserelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016